B-type natriuretic peptide in cardiovascular disease

Lancet

Volumn 362, Issue 9380, 2003, Pages 316-322

  De Lemos, James A ^a   McGuire, Darren K ^a   Drazner, Mark H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENALAPRIL; GLYCERYL TRINITRATE; HORMONE PRECURSOR; LISINOPRIL; MILRINONE; N TERMINAL BRAIN NATRIURETIC PEPTIDE; NESIRITIDE; NITROPRUSSIDE SODIUM; OMAPATRILAT; SPIRONOLACTONE; UNCLASSIFIED DRUG; VALSARTAN; VASOPEPTIDASE INHIBITOR;

AMINO TERMINAL SEQUENCE; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; DRUG SCREENING; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FAILURE; HISTORY OF MEDICINE; HUMAN; HYPOTENSION; MEASUREMENT; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; PATIENT; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; SCREENING TEST; SEQUENCE ANALYSIS; VALIDATION PROCESS;

EID: 0042198675     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13976-1     Document Type: Review

References (117)

1. Kisch B. Electron microscopy of the atrium of the heart: I Guinea pig. Exp Med Surg. 14:1956;99-112.
2. Henry J.P., Pearce J.W. The possible role of cardiac stretch receptors in the induction of changes in urine flow. J Physiol. 131:1956;572-594.
3. de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28:1981;89-94.
4. Kangawa K., Fukuda A., Minamino N., Matsuo H. Purification and complete amino acid sequence of beta-rat atrial natriuretic polypeptide (beta-rANP) of 5000 daltons. Biochem Biophys Res Commun. 119:1984;933-940.
5. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature. 332:1988;78-81.
6. Hosoda K., Nakao K., Mukoyama M., et al. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension. 17:1991;1152-1155.
7. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90:1994;195-203.
8. Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 168:1990;863-870.
9. Minamino N., Makino Y., Tateyama H., Kangawa K., Matsuo H. Characterization of immunoreactive human C-type natriuretic peptide in brain and heart. Biochem Biophys Res Commun. 179:1991;535-542.
10. Edwards B.S., Zimmerman R.S., Schwab T.R., Heublein D.M., Burnett J.C. Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 62:1988;191-195.
11. Bruneau B.G., Piazza L.A., de Bold A.J. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol. 273:1997;H2678-H2686.
12. Wiese S., Breyer T., Dragu A., et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation. 102:2000;3074-3079.
13. Mizuno Y., Yoshimura M., Harada E., et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol. 86:2000;1036-1040.
14. Onuoha G.N., Nicholls D.P., Patterson A., Beringer T. Neuropeptide secretion in exercise. Neuropeptides. 32:1998;319-325.
15. Hama N., Itoh H., Shirakami G., et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 92:1995;1558-1564.
16. Yoshimura M., Yasue H., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 87:1993;464-469.
17. Qi W., Mathisen P., Kjekshus J., et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J. 142:2001;725-732.
18. Nakao K., Mukoyama M., Hosoda K., et al. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol. 69:1991;1500-1506.
19. Doyama K., Fukumoto M., Takemura G., et al. Expression and distribution of brain natriuretic peptide in human right atria. J Am Coll Cardiol. 32:1998;1832-1838.
20. Pucci A., Wharton J., Arbustini E., et al. Localization of brain and atrial natriuretic peptide in human and porcine heart. Int J Cardiol. 34:1992;237-247.
21. Nakamura S., Naruse M., Naruse K., et al. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes. Am J Hypertens. 4:1991;909-912.
22. Sumida H., Yasue H., Yoshimura M., et al. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol. 25:1995;1105-1110.
23. Riddervold F., Smiseth O.A., Hall C., Groves G., Risoe C. Rate-induced increase in plasma atrial natriuretic factor can occur independently of changes in atrial wall stretch. Am J Physiol. 260:1991;H1953-H1958.
24. Nishimori T., Tsujino M., Sato K., Imai T., Marumo F., Hirata Y. Dexamethasone-induced up-regulation of adrenomedullin and atrial natriuretic peptide genes in cultured rat ventricular myocytes. J Mol Cell Cardiol. 29:1997;2125-2130.
25. Ladenson P.W., Bloch K.D., Seidman J.G. Modulation of atrial natriuretic factor by thyroid hormone: messenger ribonucleic acid and peptide levels in hypothyroid, euthyroid, and hyperthyroid rat atria and ventricles. Endocrinology. 123:1988;652-657.
26. Suga S., Nakao K., Hosoda K., et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 130:1992;229-239.
27. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 87:1991;1402-1412.
28. Sonnenberg J.L., Sakane Y., Jeng A.Y., et al. Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides. 9:1988;173-180.
29. Marin-Grez M., Fleming J.T., Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature. 324:1986;473-476.
30. Richards A.M., McDonald D., Fitzpatrick M.A., et al. Atrial natriuretic hormone has biological effects in man at physiological plasma concentrations. J Clin Endocrinol Metab. 67:1988;1134-1139.
31. Tonolo G., Richards A.M., Manunta P., et al. Low-dose infusion of atrial natriuretic factor in mild essential hypertension. Circulation. 80:1989;893-902.
32. Floras J.S. Sympathoinhibitory effects of atrial natriuretic factor in normal humans. Circulation. 81:1990;1860-1873.
33. Brunner-La Rocca H.P., Kaye D.M., Woods R.L., Hastings J., Esler M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 37:2001;1221-1227.
34. Atarashi K., Mulrow P.J., Franco-Saenz R. Effect of atrial peptides on aldosterone production. J Clin Invest. 76:1985;1807-1811.
35. Burnett J.C. Jr, Granger J.P., Opgenorth T.J. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol. 247:1984;F863-F866.
36. Clarkson P.B., Wheeldon N.M., Macleod C., Coutie W., MacDonald T.M. Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects. Clin Sci (Colch). 88:1995;159-164.
37. Itoh H., Pratt R.E., Dzau V.J. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest. 86:1990;1690-1697.
38. Cao L., Gardner D.G. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 25:1995;227-234.
39. Hunt P.J., Richards A.M., Espiner E.A., Nicholls M.G., Yandle T.G. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab. 78:1994;1428-1435.
40. Suga S., Nakao K., Itoh H., et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta: possible existence of "vascular natriuretic peptide system" J Clin Invest. 90:1992;1145-1149.
41. Charles C.J., Espiner E.A., Richards A.M., Donald R.A. Central C-type natriuretic peptide augments the hormone response to hemorrhage in conscious sheep. Peptides. 16:1995;129-132.
42. Davis M., Espiner E., Richards G., et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 343:1994;440-444.
43. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 350:1997;1349-1353.
44. Yamamoto K., Burnett J.C. Jr, Jougasaki M., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 28:1996;988-994.
45. Omland T., Aakvaag A., Bonarjee V.V., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 93:1996;1963-1969.
46. Hammerer-Lercher A., Neubauer E., Muller S., Pachinger O., Puschendorf B., Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta. 310:2001;193-197.
47. Dao Q., Krishnaswamy P., Kazanegra R., et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 37:2001;379-385.
48. Morrison L.K., Harrison A., Krishnaswamy P., Kazanegra R., Clopton P., Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 39:2002;202-209.
49. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 347:2002;161-167.
50. McCullough P.A., Nowak R.M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 106:2002;416-422.
51. Struthers A.D., Morris A.D. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet. 359:2002;1430-1432.
52. Motwani J.G., McAlpine H., Kennedy N., Struthers A.D. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet. 341:1993;1109-1113.
53. Richards A.M., Nicholls M.G., Yandle T.G., et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart. 81:1999;114-120.
54. Mallamaci F., Zoccali C., Tripepi G., et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 59:2001;1559-1566.
55. Okumura H., Iuchi K., Yoshida T., et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol. 104:2000;158-163.
56. Omland T., Aakvaag A., Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart. 76:1996;232-237.
57. Luchner A., Burnett J.C. Jr, Jougasaki M., et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 18:2000;1121-1128.
58. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 288:2002;1252-1259.
59. Kazanegra R., Cheng V., Garcia A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 7:2001;21-29.
60. Richards A.M., Crozier I.G., Yandle T.G., Espiner E.A., Ikram H., Nicholls M.G. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J. 69:1993;414-417.
61. Takemura G., Takatsu Y., Doyama K., et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol. 31:1998;754-765.
62. Maisel A.S., Koon J., Krishnaswamy P., et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 141:2001;367-374.
63. Yu C.M., Sanderson J.E., Shum I.O., et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure: higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J. 17:1996;1694-1702.
64. Lubien E., DeMaria A., Krishnaswamy P., et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with doppler velocity recordings. Circulation. 105:2002;595-601.
65. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 31:1998;202-208.
66. Bando M., Ishii Y., Sugiyama Y., Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med. 93:1999;507-514.
67. Bolger A.P., Sharma R., Li W., et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 106:2002;92-99.
68. Matsuo K., Nishikimi T., Yutani C., et al. Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. Circulation. 98:1998;2433-2440.
69. Wang T.J., Larson M.G., Levy D., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 90:2002;254-258.
70. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., Burnett J.C. Jnr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 40:2002;976-982.
71. Richards A.M., Doughty R., Nicholls M.G., et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation. 99:1999;786-792.
72. Maeda K., Tsutamoto T., Wada A., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 36:2000;1587-1593.
73. Stanek B., Frey B., Hulsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol. 38:2001;436-442.
74. Isnard R., Pousset F., Trochu J., et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol. 86:2000;417-421.
75. Berger R., Huelsman M., Strecker K., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 105:2002;2392-2397.
76. Richards A.M., Doughty R., Nicholls M.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol. 37:2001;1781-1787.
77. Harrison A., Morrison L.K., Krishnaswamy P., et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 39:2002;131-138.
78. Rame J.E., Sheffield M.A., Dries D.L., et al. Outcomes after emergency department discharge with a primary diagnosis of heart failure. Am Heart J. 142:2001;714-719.
79. Osca H, Zorio E, Martinez-Ortiz de urbina L, et al. Brain natriuretic peptide as an indicator of long term survival in isolated diastolic heart failure. Circulation 2001; 104 (suppl): II 501.
80. Cheng V., Kazanagra R., Garcia A., et al. A rapid test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 37:2001;386-391.
81. Nagaya N., Nishikimi T., Goto Y., et al. Plasma brain natriuretic peptideis a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J. 135:1998;21-28.
82. Richards A.M., Nicholls M.G., Yandle T.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 97:1998;1921-1929.
83. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 345:2001;1014-1021.
84. Omland T., de Lemos J.A., Morrow D.A., et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 89:2002;463-465.
85. Jernberg T., Stridsberg M., Venge P., Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 40:2002;437-445.
86. Ishii J., Nomura M., Ito M., et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta. 301:2000;19-30.
87. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 102:2000;865-870.
88. Wallen T., Landahl S., Hedner T., Nakao K., Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart. 77:1997;264-267.
89. McDonagh T.A., Cunningham A.D., Morrison C.E., et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart. 86:2001;21-26.
90. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol. 39:2002;1623-1629.
91. van Veldhuisen D.J., Genth-Zotz S., Brouwer J., et al. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol. 32:1998;1811-1818.
92. Murdoch D.R., McDonagh T.A., Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 138:1999;1126-1132.
93. Latini R., Masson S., Anand I., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 106:2002;2454-2458.
94. Tsutamoto T., Wada A., Maeda K., et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 37:2001;1228-1233.
95. 2+ infusion, and aortic constriction in pigs. Circ Res. 68:1991;638-644.
96. Sanderson J.E., Chan W.W., Hung Y.T., et al. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J. 74:1995;502-507.
97. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation. 101:2000;378-384.
98. Kawai K., Hata K., Takaoka H., Kawai H., Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J. 141:2001;925-932.
99. Koglin J., Pehlivanli S., Schwaiblmair M., Vogeser M., Cremer P., vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 38:2001;1934-1941.
100. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 355:2000;1126-1130.
101. Holmes S.J., Espiner E.A., Richards A.M., Yandle T.G., Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 76:1993;91-96.
102. Lainchbury J.G., Richards A.M., Nicholls M.G., et al. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension. 30:1997;398-404.
103. Hobbs R.E., Miller L.W., Bott-Silverman C., James K.B., Rincon G., Grossbard E.B. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 78:1996;896-901.
104. Marcus L.S., Hart D., Packer M., et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 94:1996;3184-3189.
105. Abraham W.T., Lowes B.D., Ferguson D.A., et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 4:1998;37-44.
106. Colucci W.S., Elkayam U., Horton D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 343:2000;246-253.
107. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 287:2002;1531-1540.
108. Burger A.J., Elkayam U., Neibaur M.T., et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol. 88:2001;35-39.
109. Margulies K.B., Barclay P.L., Burnett J.C. Jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation. 91:1995;2036-2042.
110. Corti R., Burnett J.C. Jr, Rouleau J.L., Ruschitzka F., Luscher T.F. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 104:2001;1856-1862.
111. Mitchell G.F., Izzo J.L. Jr, Lacourciere Y., et al. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation. 105:2002;2955-2961.
112. McClean D.R., Ikram H., Garlick A.H., Richards A.M., Nicholls M.G., Crozier I.G. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol. 36:2000;479-486.
113. Klapholz M., Thomas I., Eng C., et al. Effects of omapatrilat on hemodynamics and safety in patients with heart failure. Am J Cardiol. 88:2001;657-661.
114. Rouleau J.L., Pfeffer M.A., Stewart D.J., et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 356:2000;615-620.
115. Packer M., Califf R.M., Konstam M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation. 106:2002;920-926.
116. Messerli F.H., Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 356:2000;608-609.
117. Williams E.S., Miller J.M. Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session. J Am Coll Cardiol. 40:2002;1-18.